戊酸雌二醇/醋酸环丙孕酮

**戊酸雌二醇/醋酸环丙孕酮**
	戊酸雌二醇（顶部）和醋酸环丙孕酮（下）
组成
戊酸雌二醇	雌激素
醋酸环丙孕酮	孕激素
臨床資料
商品名（英语：Drug nomenclature）	克龄蒙（Climen），Femilar
其他名稱	EV/CPA
给药途径	口服
藥物類別（英语：Drug class）	雌激素；孕激素
法律規範狀態
法律規範	美：处方药（℞-only）;
识别信息
CAS号	108116-22-9

戊酸雌二醇/醋酸环丙孕酮（英語：Estradiol valerate/cyproterone acetate，简称：EV/CPA），以克龄蒙（英語：Climen）和Femilar等品牌销售，是戊酸雌二醇（EV，一种雌激素）和醋酸环丙孕酮（CPA，一种孕激素）的组合产品，用于绝经期激素治疗和作为妇女避孕药使用，^[1]其为口服药。^[1]克龄蒙用于绝经期激素治疗，是一种序贯制剂，含有2毫克EV和1毫克CPA。^[2]^[3]^[4]它是第一个上市的用于绝经期激素治疗的含有CPA的产品^[3]，在40多个国家有售。^[2]Femilar是一种含雌二醇的避孕药，含有1至2毫克EV和1至2毫克CPA，自1993年以来在芬兰被批准使用。^[5]

一项研究发现，单用CPA在0.5毫克/天的剂量下，5名妇女中有3名抑制排卵，在1毫克/天的剂量下，5名妇女中有5名抑制排卵。^[6]^[7]^[8]^[9]^[10]^[11]在一项研究中，108名妇女中有94.4%在第三个治疗周期内发生Femilar的排卵抑制，在另一项研究中，26名妇女在12个治疗周期内几乎100%发生排卵抑制（除了一名妇女在第一个治疗周期内排了卵）。^[5]^[12]^[1]

外部連結[编辑]

克龄蒙说明书（页面存档备份，存于互联网档案馆）（简体中文）
戊酸雌二醇片（补佳乐/克龄蒙）（页面存档备份，存于互联网档案馆）（简体中文）

参考文献[编辑]

^ ^1.0 ^1.1 ^1.2 Hirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women. Maturitas. October 1988, 10 (3): 201–13. PMID 2972897. doi:10.1016/0378-5122(88)90023-0.
^ ^2.0 ^2.1 Husmann, Friedrich. Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement. Women's Health and Menopause. Medical Science Symposia Series 11. 1997: 257–261. ISBN 978-94-010-6343-2. ISSN 0928-9550. doi:10.1007/978-94-011-5560-1_38.
^ ^3.0 ^3.1 Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. November 2003, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.
^ Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric. December 2000,. 3 Suppl 2: 21–7. PMID 11379383.
^ ^5.0 ^5.1 Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. May 2012, 28 (5): 400–8. PMC 3399636 . PMID 22468839. doi:10.3109/09513590.2012.662547.
^ Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. December 2011, 84 (6): 549–57. PMID 22078182. doi:10.1016/j.contraception.2011.04.009.
^ Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R. Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations. Acta Obstet Gynecol Scand Suppl. 1979, 88: 7–15. PMID 393050. S2CID 30486799. doi:10.3109/00016347909157223.
^ Spona J, Huber J, Schmidt JB. Inhibierung der Ovulation mit 35 μg Athinylöstradiol und 2 mg Cyproteronazetat (Diane®-35) [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]. Geburtshilfe Frauenheilkd. July 1986, 46 (7): 435–8. PMID 3093307. doi:10.1055/s-2008-1026659 （德语）.
^ Spona J, Huber J. Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate. Gynecol Obstet Invest. 1987, 23 (3): 184–93. PMID 2954886. doi:10.1159/000298860.
^ Spona, J.; Huber, J.; Schmidt, J. B. Ovulation inhibitory effect of SH B 209 AE (Diane-35)—a new antiandrogen-estrogen combination. Schindler, Adolf E. (编). Antiandrogen-Estrogen Therapy for Signs of Androgenization. Berlin, Boston: De Gruyter. 1987-12-31: 51–58. ISBN 9783110866902. doi:10.1515/9783110866902-006.
^ Hammerstein, J. Antiandrogens: Clinical Aspects. Hair and Hair Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg. 1990: 827–886. ISBN 978-3-642-74614-7. doi:10.1007/978-3-642-74612-3_35.
^ Hirvonen E, Allonen H, Anttila M, Kulmala Y, Ranta T, Rautiainen H, Sipilä P, Ylöstalo P. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. January 1995, 21 (1): 27–32. PMID 7731379. doi:10.1016/0378-5122(94)00856-3.

这是一篇关于类固醇的小作品。你可以通过编辑或修订扩充其内容。

[pmid2972897-1] 1.0 ^1.1 ^1.2 Hirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women. Maturitas. October 1988, 10 (3): 201–13. PMID 2972897. doi:10.1016/0378-5122(88)90023-0.

[Husmann1997-2] 2.0 ^2.1 Husmann, Friedrich. Clinical Experiences with a Combination of Estradiol Valerate and Cyproterone Acetate for Hormone Replacement. Women's Health and Menopause. Medical Science Symposia Series 11. 1997: 257–261. ISBN 978-94-010-6343-2. ISSN 0928-9550. doi:10.1007/978-94-011-5560-1_38.

[pmid14644837-3] 3.0 ^3.1 Schneider HP. Androgens and antiandrogens. Ann. N. Y. Acad. Sci. November 2003, 997 (1): 292–306. Bibcode:2003NYASA.997..292S. PMID 14644837. S2CID 8400556. doi:10.1196/annals.1290.033.

[pmid11379383-4] Schneider HP. The role of antiandrogens in hormone replacement therapy. Climacteric. December 2000,. 3 Suppl 2: 21–7. PMID 11379383.

[pmid22468839-5] 5.0 ^5.1 Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. May 2012, 28 (5): 400–8. PMC 3399636 . PMID 22468839. doi:10.3109/09513590.2012.662547.

[pmid22078182-6] Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. December 2011, 84 (6): 549–57. PMID 22078182. doi:10.1016/j.contraception.2011.04.009.

[pmid393050-7] Spona J, Schneider WH, Bieglmayer C, Schroeder R, Pirker R. Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations. Acta Obstet Gynecol Scand Suppl. 1979, 88: 7–15. PMID 393050. S2CID 30486799. doi:10.3109/00016347909157223.

[pmid3093307-8] Spona J, Huber J, Schmidt JB. Inhibierung der Ovulation mit 35 μg Athinylöstradiol und 2 mg Cyproteronazetat (Diane®-35) [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]. Geburtshilfe Frauenheilkd. July 1986, 46 (7): 435–8. PMID 3093307. doi:10.1055/s-2008-1026659 （德语）.

[pmid2954886-9] Spona J, Huber J. Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate. Gynecol Obstet Invest. 1987, 23 (3): 184–93. PMID 2954886. doi:10.1159/000298860.

[SponaHuber1987-10] Spona, J.; Huber, J.; Schmidt, J. B. Ovulation inhibitory effect of SH B 209 AE (Diane-35)—a new antiandrogen-estrogen combination. Schindler, Adolf E. (编). Antiandrogen-Estrogen Therapy for Signs of Androgenization. Berlin, Boston: De Gruyter. 1987-12-31: 51–58. ISBN 9783110866902. doi:10.1515/9783110866902-006.

[Hammerstein1990-11] Hammerstein, J. Antiandrogens: Clinical Aspects. Hair and Hair Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg. 1990: 827–886. ISBN 978-3-642-74614-7. doi:10.1007/978-3-642-74612-3_35.

[pmid7731379-12] Hirvonen E, Allonen H, Anttila M, Kulmala Y, Ranta T, Rautiainen H, Sipilä P, Ylöstalo P. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas. January 1995, 21 (1): 27–32. PMID 7731379. doi:10.1016/0378-5122(94)00856-3.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]